Ang Celina, O'Reilly Eileen M, Abou-Alfa Ghassan K
Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Recent Results Cancer Res. 2013;190:225-46. doi: 10.1007/978-3-642-16037-0_15.
Cytotoxic chemotherapy, hormonal agents, and immunotherapy have been tested in hepatocellular cancer (HCC) with marginal efficacy to date. Recent insights into the molecular pathogenesis of HCC have identified several aberrant signaling pathways that have served as targets for novel therapeutic agents. These discoveries have been translated into the clinical realm with the use of the antiangiogenic and the Raf kinase inhibitor, sorafenib, and have revealed the potential of targeted agents to produce clinically meaningful survival benefits in patients with advanced HCC. Efforts continue in the quest to improve the outcome of HCC patients through the development and evaluation of other targeted agents, and to better understand the interactions between the underlying disease biology and response to therapy. Several pathways are now implicated in hepatocarcinogenesis and agents that target these pathways continue to be developed.
细胞毒性化疗、激素药物和免疫疗法至今在肝细胞癌（HCC）治疗中的疗效甚微。近期对HCC分子发病机制的深入研究发现了几条异常信号通路，这些通路已成为新型治疗药物的靶点。这些发现已通过使用抗血管生成药物和Raf激酶抑制剂索拉非尼应用于临床领域，并揭示了靶向药物在晚期HCC患者中产生具有临床意义的生存获益的潜力。通过研发和评估其他靶向药物以改善HCC患者预后，并更好地理解潜在疾病生物学与治疗反应之间的相互作用的努力仍在继续。目前有几条通路与肝癌发生有关，针对这些通路的药物仍在不断研发。
